Epithelial Mesenchymal Transition as Targets for Cancer Therapy

Krishnaveni M
Additional contact information
Krishnaveni M: Department of Biochemistry, Periyar University, India

Novel Approaches in Drug Designing & Development, 2017, vol. 3, issue 1, 14-18

Abstract: Most of the primary epithelial cancers are developed by increased epithelial cell proliferation and angiogenesis. When these cancer cells broke, they shed their contents in to the blood stream as well as in to the lymphatic vessels and stay at sites called as secondary site via metastasis mediated by epithelial mesenchymal transition giving cell a mesenchymal nature that are more prevalent in cancers of various types. Irreversible mutation and reversible epigenetic changes like methylation in DNA, histone modifications, altered miRNA also cause cancer as they are prone to deletion, amplification, recombination. Epithelial mesenchymal transition develops resistance to treatment drugs. Hence, using EMT as targets for cancer will be of much useful and in the present review few targets that could alter EMT is discussed. So, any natural compound that could act on the process of EMT i.e able to inhibit the transition in to mesenchymal cell in order to maintain architecture and adhesive property of cell.

Keywords: juniper publishers; drug designing pdf; drug designing articles; drug designing abstract; drug designing journal; modern approaches in drug designing journal; drug designing & intellectual properties international journal; peer reviewed open access journals; high impact journals; juniper publishers review (search for similar items in EconPapers)
Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/napdd/pdf/NAPDD.MS.ID.555604.pdf (application/pdf)
https://juniperpublishers.com/napdd/NAPDD.MS.ID.555604.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jnapdd:v:3:y:2017:i:1:p:14-18

DOI: 10.19080/NAPDD.2017.03.555604

Access Statistics for this article

Novel Approaches in Drug Designing & Development is currently edited by Sophia Mathis

More articles in Novel Approaches in Drug Designing & Development from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().